• 1
    D’Amico G. The commonest glomerulonephritis in the world. Iga Nephropathy Q J Med 1987; 64: 70927
  • 2
    Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990; 89: 209215.
  • 3
    Conley ME, Cooper MD, Michael AF et al. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylac-toid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 1980; 66: 14326.
  • 4
    Valentijn RM, Radl J, Haaijman JJ, Vermeer BJ, Weening JJ, Kauffmann RH, Daha MR, Van Es LA. Circulating and mesangial secretory component-binding IgA1 in primary IgA nephropathy. Kidney Int 1984; 26: 7606.
  • 5
    Kim P-K, Mong F-C, Lee JS, Jeong HJ, Choi IJ. Clinicopathological correlation in forty-two children with IgA nephropathy. Child Nephrol Urol 1988; 9: 218.
  • 6
    Koselj M, Rott T, Kandus A, Vizjak A, Malovrh M. Donor-transmitted IgA nephropathy. long-term follow-up of kidney donors and recipients. Transplant Proc 1997; 29: 34067.
  • 7
    Harper SJ, Allen AC, Pringle JH, Feehally J. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridization for J chain mRNA. J Clin Patho 1996; 149: 3842.
  • 8
    De Fijter JW, Eijgenraam JW, Braam CA, Holmgren J, Daha MR, Van Es LA, Van Den Wall Bake AW. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int 1996; 50: 95261.
  • 9
    Barratt J, Bailey EM, Buck KS, Mailley J et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999; 33: 104957.
  • 10
    Van Den Wall Bake AWL, Daha MR, Van Den Ark A, Hiemstrps Radl J, Van Es A. Serum levels and in vitro production of IgA subclasses in patients with primary IgA nephropathy. Clin Exp Immunol 1988; 74: 11520.
  • 11
    Jones C, Mermelstein N, Kincaid-Smith P, Powell H, Robterson D. Quantitation of human serum polymeric IgA, IgA1 and IgA2 immunoglobulin by enzyme immunoassay. Clin Exp Immunol 1988; 72: 3449.
  • 12
    Layward L, Allen AC, Hattersley JM, Harper SJ, Feehally J. Elevation of IgA in IgA nephropathy is localized in the serum and not saliva and is restricted to the IgA1 subclass. Nephrol Dial Transplant 1993; 8: 258.
  • 13
    Hiki Y, Tanaka A, Kokubo T, Iwase H, Nishikido J, Hotta K, Kobayashi Y. Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry. Biochem Biophys Res Commun 2000; 271: 26874.
  • 14
    Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 1999; 10: 176371.
  • 15
    Roccatello D, Sena LM. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Laboratory Invest 1993; 69: 71423.
  • 16
    Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, Kobayashi Y. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998; 9: 204854.
  • 17
    Monteiro RC, Halbwachs-Mecarelli L, Roque-Barreire MC, Noel LH, Berger J, Lesavre P. Charge and size of mesangial IgA in IgA nephropathy. Kidney Int 1985; 28: 66671.
  • 18
    Monteiro RC, Halbwachs-Mecarelli T, Berger J, Lesavre P. Characteristics of eluted IgA in primary IgA nephropathy. Contr Nephrol 1984; 40: 10711.
  • 19
    Allen AC, Bailey EM, Buck KS, Barratt J, Brenchley PEC, Feehally J. O-glycosylation of mesangial IgA1 in IgA nephropathy. J Am Soc Nephrol 1999; 10: 506A.
  • 20
    Gómez-Guerrero C, Gonzalez E, Egido J et al. Evidence for a specific IgA receptor in rat and human mesangial cells. J Immunol 1993; 151: 717281.
  • 21
    Gómez-Guerrero C, Duque N, Egido J et al. Mesangial cells possess an asialo-glycoprotein receptor with affinity for human immunoglobulin A. J Am Soc Nephrol 1998; 9: 56876.
  • 22
    Diven SC, Caflisch CR, Hammond DK, Weigel PH, Oka JA, Goldblum RM. IgA induced activation of human mesangial cells. independent of Fc alphaR1 (CD 89). Kidney Int 1998; 54: 83747.
  • 23
    Bagheri N, Chintalacharuvu SR, Emancipator SN et al. Proinflam-matory cytokines regulate Fc alpha R expression by humanmesangial cells in vitro. Clin Exp Immunol 1997; 107: 4049.
  • 24
    Duque N, Gomez-Guerrero C, Egido J et al. Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcriptionfactor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol 1997; 159: 347482.
  • 25
    Gomez-Guerrero C, Duque N, Egido J et al. Stimulation of Fc (alpha) receptors induces tyrosine phosphorylation of phospholipase C-gamma (1), phosphatidylinositol phosphate hydrolysis, and Ca2+mobilization in rat and human mesangial cells. J Immunol 1996; 156: 436976.
  • 26
    Van Den Dobbelsteen ME, Van Der Woude FJ, Schroeijers WE, Van Den Wall Bake AW, Van Es LA, Daha MR. Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6. Kidney Int 1994; 46: 5129.
  • 27
    Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, Egido J et al. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol 1994; 153: 524755.
  • 28
    Lopez-Armada MJ, Gomez-Guerrero C, Egido J et al. Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of TGF-beta. Clin Exp Immunol 1997; 110: 22632.
  • 29
    Leung JC, Tang SC, Lam MF, Chan TM, Lai KN. Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy. Kidney Int. 2001; 59: 27785.
  • 30
    Greenwood FC, Hunter WM, Glover JS. The preparation of (125I) labeled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114.
  • 31
    Troyer DA, Kreisberg JI. Isolation and study of glomerular cells. Meth Enzymol 1990; 191: 14152.
  • 32
    Trafford AW, Sibbring GC, Diaz ME. The effects of low concentrations of caffeine on spontaneous Ca release in isolated rat ventricular myocytes. Cell Calcium 2000; 28: 26976.
  • 33
    Catchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1991; 51: 66072.
  • 34
    Berger J, Hinglais N. Les depots intercapillaires d’IgA-IgG. J Urol Nephrol 1968; 74: 6945.
  • 35
    Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide: a neglected disease in the United States? Am J Med 1988; 84: 12932.
  • 36
    Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988; 12: 3407.
  • 37
    D’Amico G, Colasanti G, Barbiano di Belgioioso G et al. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. Semin Nephrol 1987; 7: 3558.
  • 38
    Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199207.
  • 39
    Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine 1994; 73: 79102.
  • 40
    Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC. Savino DA. Prognostic indicators in children with IgA nephropathy – report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 1994; 8: 1520.
  • 41
    Briganti EM, Dowling J, Finlay M et al. The incidence of biopsyproven glomerulonephritis in Australia. Nephrol Dial Transplant 2001; 16: 13647.
  • 42
    Maisonneuve P, Agodoa L, Gellert R et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000; 35: 15765.
  • 43
    Russell MW, Mestecky J, Julian BA, Galla JH. IgA-associated renal diseases. antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986; 6: 7486.
  • 44
    Issacs K, Miller F, Lane B et al. Experimental model for IgA nephropathy. Clin Immunol Immunopathol 1981; 20: 41926.
  • 45
    Rifai A. Experimental models for IgA-associated nephritis. Kidney Int 1987; 31: 17.
  • 46
    Van Dixhoorn MGA, Gorter A, Sato T, Van Der Wal AM, Van Eendenburg JDH, Rozing J, Daha MR, De Heer E. Induction of microhematuria by an IgA isotype switch variant of a monoclonal anti-Thy-1.1 antibody in the rat. Kidney Int 1996; 50: 161223.
  • 47
    Flogeg J, Feehally J. IgA Nephropathy: Recent Developments. J Am Soc Nephrol 2000; 11: 2395403.
  • 48
    D’Amico G. Pathogenesis of immunoglobulin A nephropathy. Curr Opin Nephrol Hypertens 1998; 7: 24750.
  • 49
    Westerhuis R, Kitahara M, Flogeg J et al. IgA-Nephropathy: how does IgA activate the mesangial cell? Clin Exp Nephrol 2001; 5: 17.